Fig. 8.

Effects of pre-treatment with a a PI3K antagonist (LY294002); b an Nrfr2 antagonist (ML385) given alone or in combination c on the beneficial action of δ-TT against t-BHP-induced MC3T3-E1 damage. Cells were treated with LY294002 (10 μM) or ML385 (7.5 µM) 2 h before δ-TT (10 µg/ml) and t-BHP (250 μM for 3 h). MTT assay was performed to analyze cell viability. Data represented the mean ± SEM of six replicates within a single experiment. ***p < 0.001 vs controls; °p < 0.05, °°p < 0.01, °°°p < 0.001 vs t-BHP; ^###p < 0.001 vs LY294002 or ML385 + t-BHP